Lovastatin

證據等級: L5

預測適應症: 10 個

Lovastatin: From Hyperlipidemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Lovastatin is a well-established HMG-CoA reductase inhibitor (statin) used globally to treat various forms of hyperlipidemia by suppressing hepatic cholesterol synthesis and upregulating LDL receptors. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), with 3 clinical trials and 19 publications identified in this therapeutic area — however, most evidence concerns competing drugs, and the direct clinical data for Lovastatin in HoFH reveals a critical mechanistic caveat tied to LDL receptor (LDLR) function.

Quick Overview

Item	Content
Original Indication	Primary hypercholesterolemia / Hyperlipidemia (globally established; not registered in Singapore)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.89%
Evidence Level	L3
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for Lovastatin is not available in the current evidence pack. Based on established pharmacology, Lovastatin is a prodrug belonging to the statin class. After hepatic conversion to its active acid form, it competitively inhibits HMG-CoA reductase — the rate-limiting enzyme in cholesterol biosynthesis. This reduces endogenous cholesterol production and triggers compensatory upregulation of LDL receptors (LDLR) on hepatocyte surfaces, increasing LDL-C clearance from plasma. In patients with at least one functional LDLR allele, this mechanism reliably lowers LDL-C by 25–45%.

The challenge for HoFH lies in its genetics: biallelic loss-of-function mutations in the LDLR gene leave patients with severely deficient or absent receptor activity. In receptor-negative HoFH (both alleles non-functional), Lovastatin's principal mechanism of action — inducing LDLR upregulation — simply cannot operate. A 1988 clinical study (PMID 3397806) confirmed this directly: Lovastatin at 2 mg/kg/day in three receptor-negative HoFH children produced no decrease in LDL-C levels or LDL turnover. In contrast, a 1986 JAMA case report (PMID 3534334) demonstrated that Lovastatin could normalize cholesterol in a post-liver-transplant HoFH child — precisely because the transplant restored approximately 60% of normal LDLR activity.

This distinction is clinically decisive. Receptor-defective HoFH variants (compound heterozygotes retaining partial LDLR function) may derive some benefit from Lovastatin, while receptor-negative patients are unlikely to respond. The TxGNN model's prediction captures Lovastatin's broad relevance to the cholesterol metabolism pathway, but the clinical reality is that HoFH represents a pharmacogenomically stratified population where LDLR residual activity is the critical determinant of treatment response. Current standard-of-care trials for HoFH focus on agents that bypass LDLR dependence entirely — such as ezetimibe (intestinal cholesterol absorption blockade) and PCSK9 inhibitors — which further limits Lovastatin's repurposing value here.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03884452	Phase 3	Completed	50	Ezetimibe 10 mg added to atorvastatin or simvastatin in HoFH — primary endpoint was LDL-C reduction; established the ezetimibe + statin combination as a reference standard
NCT03510715	Phase 3	Completed	18	Alirocumab (PCSK9 inhibitor) in children/adolescents aged 8–17 with HoFH — evaluated LDL-C reduction at Weeks 12, 24, and 48; represents current biologic first-line therapy
NCT03885921	Phase 3	Completed	44	24-month open-label safety extension of NCT03884452 — long-term tolerability of ezetimibe co-administered with atorvastatin or simvastatin in HoFH patients

Important note: None of these trials directly investigates Lovastatin as an intervention for HoFH. They characterize the current competitive treatment landscape — agents that Lovastatin would need to outperform or complement in this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12034651	2002	RCT	Circulation	Multicenter, double-blind RCT of ezetimibe + atorvastatin or simvastatin in 50 HoFH patients — additional 15–20% LDL-C reduction vs. statin alone; demonstrated ezetimibe utility in LDLR-independent pathway
3397806	1988	Clinical Study	J Pediatrics	Key negative finding for Lovastatin in HoFH: 3 receptor-negative HoFH children treated with Lovastatin 2 mg/kg/day — no decrease in LDL-C levels or LDL turnover, confirming LDLR dependence of statin efficacy
1785747	1991	Clinical Study	Anales Espanoles de Pediatria	Lovastatin combined with probucol and cholestyramine in 2 HoFH patients — moderate cholesterol reduction observed in patients classified as receptor-defective (residual LDLR activity), not receptor-negative
29284604	2018	Cohort	Arterioscler Thromb Vasc Biol	HoFH patients with identical LDLR mutations showed highly variable LDLR protein expression, explaining differential response to evolocumab; underscores that genotype alone does not predict residual receptor function
3534334	1986	Case Report	JAMA	Post-liver-transplant HoFH child treated with Lovastatin (mevinolin) — cholesterol normalized once transplant restored ~60% of normal LDLR activity; mechanistically confirms that Lovastatin efficacy in HoFH is gated by receptor availability
7229037	1981	In Vitro	J Clin Invest	ML-236b (compactin, a statin precursor) on HoFH fibroblasts — receptor-defective cells showed compensatory LDL receptor upregulation; receptor-negative cells did not respond; foundational mechanistic basis for LDLR-dependence
2209665	1990	Clinical Study	Eur J Pediatrics	LDL plasmapheresis with and without Lovastatin in a 7-year-old HoFH girl — Lovastatin did not meaningfully reduce baseline LDL-C but appeared to slow cholesterol rebound between apheresis sessions
14727947	2003	Review	Am J Cardiovasc Drugs	Ezetimibe pharmacology and clinical efficacy review — ~12% additional LDL-C reduction on top of statin therapy in hypercholesterolemia including HoFH subgroup; rationalizes LDLR-independent add-on strategies
15554726	2004	Review	Am J Cardiovasc Drugs	Ezetimibe/simvastatin combination — complementary dual blockade of intestinal cholesterol absorption and hepatic cholesterol synthesis; relevant benchmark for multi-mechanism strategies in HoFH
29233637	2018	Case Report	J Clin Lipidology	Compound heterozygous FH in a Chinese pediatric patient with de novo and transmitted LDLR mutations — illustrates phenotypic and genetic complexity of HoFH subtypes relevant to treatment selection

Singapore Market Information

Lovastatin currently has no registered products with the Health Sciences Authority (HSA) of Singapore (0 authorizations on record). Any clinical or commercial development in Singapore would require a full new drug registration process.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model's 99.89% confidence score reflects Lovastatin's deep mechanistic relevance to cholesterol homeostasis broadly, but published clinical data in HoFH specifically reveals a binary response pattern: receptor-negative HoFH patients — who represent the majority of severe cases — show no measurable LDL-C response to Lovastatin, while receptor-defective variants with residual LDLR activity may derive partial benefit. All three identified Phase 3 trials test competing agents (ezetimibe, alirocumab) that bypass LDLR dependence, and Lovastatin holds no Singapore market authorization.

To proceed, the following is needed:

LDLR subtype stratification: Characterize the target HoFH population by residual LDLR activity (receptor-negative vs. receptor-defective); Lovastatin repurposing is only viable in the receptor-defective subgroup
Safety package: Obtain full package insert data including contraindications, key warnings, and drug interaction profile (currently absent) — particularly critical given the known risk of myopathy and rhabdomyolysis with statin class agents
Combination therapy positioning: If receptor-defective patients are identified, evaluate Lovastatin as part of a multi-drug regimen (e.g., with ezetimibe or bile acid sequestrants) rather than as monotherapy, consistent with historical combination approaches
Singapore registration pathway: Develop a regulatory strategy with HSA since Lovastatin is currently unregistered in Singapore
Pharmacogenomic baseline: Consider SLCO1B1 rs4149056 genotyping in the target population given known associations with statin-associated muscle symptoms, particularly relevant for long-term therapy in FH patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.